NCT04358016

Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding

The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 54 (actual)
• Sponsor: Changhai Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.

Detailed description

54 cirrhotic patients with uppre-gastrointestinal bleeding were entrolled and were distributed into terlipressin group and control group at 1:1 rate. Patients in Terlipressin group received 1mg/6h of terlipressin intravenously for 5 days, and patients in control group recerved 1mg/12h of Somatostatin intravenously for 5 days. At enrollment, 24h,48h,72,and 1week, the renal function index level( serum creatinine,urine biochemistry and Urinary tubule injury index etc) were tested.

Conditions

• Cirrhosis, Liver
• Upper Gastrointestinal Bleeding

Interventions

Type	Name	Description
DRUG	Terlipressin	Evaluate the effect of Terlipression on the occurance of acute kidney injury in patients with upper-gastroentestinal bleeding
DRUG	Somatostatin	Somatostatin

Timeline

• Start date: 2018-01-01
• Primary completion: 2020-01-01
• Completion: 2020-03-01
• First posted: 2020-04-22
• Last updated: 2020-04-22

Locations

1 site across 1 country: China